HALO News and Press, Halozyme Therapeutics Inc. From 07/12/21

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse - Janssen's DARZALEX FASPRO® Now the F...

Michael Vi/iStock Editorial via Getty Images Johnson & Johnson's (JNJ) Janssen division received two European Commission ("EC") marketing authorizations for Darzalex SC, a subcutaneous formulation of Darzalex (daratumumab). The first is for Darzalex SC in combination with Velcade (bo...

Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma - Janssen received European approval for DARZALEX® (daratumu...

Halozyme’s drug delivery technology provides the opportunity to administer large volume subcutaneous injections that may enable dosing intervals of every three months and up to six months or longer for ViiV’s pipeline of HIV medicines ViiV Healthcare, the g...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives exclu...

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV Halozyme's drug delivery technology provides the opportunity to administer large volume subcuta...

Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire SAN DIEGO , June 1, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) t...

Halozyme to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO , May 28, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will participate at the following investor conferences: The Goldman Sachs 42nd Ann...

Halozyme is currently in the stalwart phase with approximately less than 50% more upsides. The company shifted focus to employing a low-risk business model. They're out-licensing their Enhanze technology to other large pharmas. With an increasing number of blockbusters being refor...

Janssen Pharmaceutica, a unit of Johnson & Johnson ([[JNJ]] +0.6%) has received two positive opinions from the European Medicines Agency ((EMA)) to broaden the current marketing authorization for DARZALEX (daratumumab) subcutaneous formulation ((SC)).One recommendation is for it...